Setting innate immunity in motion.
Kinimmune is advancing KIN-112, a proprietary peptide–TLR agonist designed to drive powerful, localized immune activation and improve therapeutic responsiveness in patients with solid tumors.
About
Local activation. Systemic potential.
From localized treatment at the tumor to immune activity that can reach disease elsewhere in the body.
Kinimmune is developing localized immunotherapies designed to activate the immune system at the site of a tumor. Our lead program, KIN-112, combines a proprietary peptide with a TLR agonist to keep treatment concentrated within the tumor and mobilize immune cells against cancer. This approach is designed to deliver powerful local immune activation while limiting exposure throughout the rest of the body.